[Metamizole and agranulocytosis. What is happening in Spain?].
作者信息
Garcia Del Campo C Cristina, Murcia Soler Miguel, Martinez-Mir Inocencia, Palop Larrea Vicente
机构信息
Asociación de Afectados por Fármacos (ADAF), Jávea, Alicante, España.
Departamento de Salud de La Ribera, Conselleria de Sanitat, Valencia, España.
出版信息
Aten Primaria. 2025 Feb;57(2):103088. doi: 10.1016/j.aprim.2024.103088. Epub 2024 Oct 30.
Abstract
摘要
相似文献
1
[Metamizole and agranulocytosis. What is happening in Spain?].[安乃近与粒细胞缺乏症。西班牙正在发生什么？]
Aten Primaria. 2025 Feb;57(2):103088. doi: 10.1016/j.aprim.2024.103088. Epub 2024 Oct 30.
2
Risk of agranulocytosis with metamizole in comparison with alternative medications based on health records in Spain.基于西班牙健康记录的药物比较，使用美洛昔康与使用麦角胺的粒细胞缺乏风险。
Eur J Clin Pharmacol. 2024 Oct;80(10):1503-1514. doi: 10.1007/s00228-024-03706-5. Epub 2024 Jun 22.
3
[Adequacy of the safety of metamizole and agranulocytosis].[安乃近安全性与粒细胞缺乏症的充分性]
Aten Primaria. 2021 Jun-Jul;53(6):102047. doi: 10.1016/j.aprim.2021.102047. Epub 2021 Apr 3.
4
Agranulocytosis attributed to metamizole: An analysis of spontaneous reports in EudraVigilance 1985-2017.归因于甲氨蝶呤的粒细胞缺乏症：EudraVigilance 1985-2017 年自发报告分析。
Basic Clin Pharmacol Toxicol. 2020 Feb;126(2):116-125. doi: 10.1111/bcpt.13310. Epub 2019 Oct 7.
5
[The use of metamizole as a risk factor in the occurrence of agranulocytosis].[安乃近作为粒细胞缺乏症发生的一个风险因素的应用]
Vutr Boles. 1988;27(2):80-5.
6
[Agranulocytosis after use of metamizole - an underestimated risk?].[使用安乃近后发生粒细胞缺乏症——一种被低估的风险？]
Laryngorhinootologie. 2020 Oct;99(10):707-712. doi: 10.1055/a-1190-4445. Epub 2020 Jun 25.
7
A Case Report on Metamizole-Induced Agranulocytosis: Is the Benefit Worth the Risk?关于安乃近致粒细胞缺乏症的病例报告：益处是否值得冒风险？
Cureus. 2023 Jan 31;15(1):e34467. doi: 10.7759/cureus.34467. eCollection 2023 Jan.
8
High-Throughput Sequencing to Investigate Associations Between HLA Genes and Metamizole-Induced Agranulocytosis.高通量测序研究HLA基因与安乃近诱导的粒细胞缺乏症之间的关联。
Front Genet. 2020 Aug 21;11:951. doi: 10.3389/fgene.2020.00951. eCollection 2020.
9
Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis.瑞典北部安乃近的使用模式及粒细胞缺乏症的风险评估
Pharmacoepidemiol Drug Saf. 2002 Apr-May;11(3):239-45. doi: 10.1002/pds.697.
10
Metamizole and the risk of drug-induced agranulocytosis and neutropenia in statutory health insurance data.甲灭酸与法定健康保险数据中药物诱导的粒细胞缺乏症和中性粒细胞减少症的风险。
Naunyn Schmiedebergs Arch Pharmacol. 2020 Apr;393(4):681-690. doi: 10.1007/s00210-019-01774-4. Epub 2019 Dec 7.
本文引用的文献
1
[Adequacy of the safety of metamizole and agranulocytosis].[安乃近安全性与粒细胞缺乏症的充分性]
Aten Primaria. 2021 Jun-Jul;53(6):102047. doi: 10.1016/j.aprim.2021.102047. Epub 2021 Apr 3.
Zotero 插件